Perioperative treatment and biomarker analysis of LP002, an anti‐PD‐L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer

BACKGROUND: The addition of immune checkpoint inhibitors to perioperative chemotherapy in operable gastric or gastroesophageal junction (GEJ) cancer has become one of the research hotspots, while reliable biomarkers for efficacy are lacking. We conducted a phase 1 trial to assess the safety and effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Jia‐lin, Zhang, Bo, Xu, Jian‐ping, Qi, Ling, Xin, Dao, Wang, Lin, Wang, Bing‐zhi, Tian, Yan‐tao, Li, Yong, Huang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028060/
https://www.ncbi.nlm.nih.gov/pubmed/36341590
http://dx.doi.org/10.1002/cam4.5414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028060/
https://www.ncbi.nlm.nih.gov/pubmed/36341590
http://dx.doi.org/10.1002/cam4.5414

Ejemplares similares